Checkpoint Inhibitors · CAR-T · Bispecifics · irAE Management · GCC Context · Interactive Toxicity Grader
Immunotherapy represents a paradigm shift from direct cytotoxic therapy to immune modulation. Cancer cells evade the immune system through multiple mechanisms — immunotherapy disrupts these evasion strategies.
Nurse Key Point: A patient on pembrolizumab who stops treatment may develop an irAE months later. Always take immunotherapy history in any oncology patient presenting with new symptoms.
Tumour cells overexpress PD-L1 which binds PD-1 on T-cells, sending an "off" signal. PD-1/PD-L1 inhibitors block this interaction, re-activating T-cells to attack the tumour. Like removing the "brakes" from T-cells.
CTLA-4 is an inhibitory receptor on T-cells that downregulates early immune activation. Ipilimumab blocks CTLA-4, amplifying the initial T-cell response. Mechanism acts earlier in the immune activation sequence — hence higher systemic inflammation.
When the immune brake is removed, T-cells can attack normal tissues too. This causes immune-related adverse events (irAEs) — effectively autoimmune conditions. Any organ can be affected. Management requires immunosuppression (steroids).
| Cancer Type | Common Agent | Setting |
|---|---|---|
| NSCLC | Pembrolizumab, Atezolizumab, Durvalumab | 1st line, maintenance |
| Melanoma | Nivolumab + Ipilimumab, Pembrolizumab | Adjuvant, advanced |
| RCC (Renal) | Nivolumab + Ipilimumab, Pembrolizumab | 1st line advanced |
| Bladder/Urothelial | Pembrolizumab, Atezolizumab | 2nd line, maintenance |
| TNBC (Breast) | Pembrolizumab + chemo | Neoadjuvant, advanced |
| MSI-high tumours | Pembrolizumab | Any solid tumour (tumour agnostic) |
| Head & Neck SCC | Pembrolizumab, Nivolumab | 1st/2nd line |
| HCC (Liver) | Atezolizumab + bevacizumab | 1st line advanced |
Most widely used checkpoint inhibitor in GCC. Approved across multiple tumour types (NSCLC, melanoma, TNBC, HNSCC, MSI-high, RCC, bladder, HCC). PD-L1 TPS ≥1% required for some indications.
Approved for melanoma, NSCLC, RCC, HNSCC, urothelial, HCC, oesophageal. Often combined with ipilimumab (dual checkpoint blockade) — significantly higher irAE rate in combination.
NSCLC, TNBC, HCC (+ bevacizumab), urothelial. 60-min infusion, may reduce to 30 min if tolerated.
Stage III NSCLC post-chemoradiation (PACIFIC regimen), SCLC, biliary tract. 60-min infusion. Widely available in GCC.
Merkel cell carcinoma, urothelial maintenance. Requires pre-medication with antihistamine + paracetamol to reduce infusion reactions.
CTLA-4 blockade amplifies earlier T-cell activation — causing more systemic inflammation than PD-1/PD-L1 agents. Colitis is particularly common (30-40% of patients). Combination with nivolumab is now standard in melanoma and RCC first line.
Checkpoint inhibitor infusion reactions are different from chemotherapy hypersensitivity — they tend to be milder and less acute. Cytokine-mediated reactions (fever, chills, rigors) are more common than anaphylaxis. However, Grade 3-4 reactions do occur and require immediate management.
Immune-related adverse events (irAEs) result from immune overactivation affecting normal tissues. The mechanism mirrors autoimmune disease. Unlike chemotherapy side effects, irAEs can affect any organ system and can occur at any time — including months after completing treatment.
CTCAE Grade 1 ●
Mild symptoms, no intervention needed. Continue immunotherapy with monitoring.
CTCAE Grade 2 ●
Moderate symptoms, limiting instrumental ADLs. Hold immunotherapy. Start oral steroids.
CTCAE Grade 3-4 ●
Severe/life-threatening. HOLD immunotherapy. IV steroids. Urgent specialist referral.
| Grade | Description |
|---|---|
| 1 | Radiological changes only, no symptoms |
| 2 | Symptomatic, not on O2, limiting ADLs |
| 3 | Severe symptoms, requiring O2 — hospitalise |
| 4 | Life-threatening, ventilatory support required |
Grade 3-4 pneumonitis = PERMANENTLY DISCONTINUE immunotherapy
Ask patient to keep written/app record: frequency per day, consistency (Bristol stool chart), presence of blood/mucus, nocturnal stools (marker of severity).
| Grade | Stools Above Baseline |
|---|---|
| 1 | <4 stools/day above baseline |
| 2 | 4-6 stools/day above baseline — hold immunotherapy |
| 3 | ≥7 stools/day above baseline, hospitalise |
| 4 | Life-threatening (perforation, haemorrhage, ischaemia) |
Grade 2+ colitis requires urgent gastroenterology referral for colonoscopy and possible infliximab decision.
Endocrinopathies are often permanent — patients require lifelong hormone replacement even if immunotherapy is discontinued.
Select the organ system affected, then select the description that best matches the patient's symptoms to receive CTCAE grading and nursing management guidance.
| Grade | Immunotherapy | Initial Treatment | Route | Duration |
|---|---|---|---|---|
| 1 | Continue | Symptomatic treatment only (antihistamines, topical steroids for skin) | Topical / None | Monitor closely |
| 2 | HOLD | Prednisolone 0.5–1 mg/kg/day | Oral | Until Grade ≤1, then taper |
| 3 | HOLD | IV Methylprednisolone 1–2 mg/kg/day | IV — hospitalise | Until Grade ≤1, then convert oral, taper over 4-6 weeks |
| 4 | PERMANENTLY DISCONTINUE | IV Methylprednisolone 1–2 mg/kg/day ± pulsed steroids | IV — ICU consideration | Extended taper over 6+ weeks after recovery |
Critical: Premature steroid taper is a common cause of irAE relapse. Minimum 4-6 weeks taper. If symptoms worsen on taper — return to higher dose. Do NOT rush tapering for treatment convenience.
Second-line for steroid-refractory colitis (if >3-5 days steroids and no improvement). Given as IV infusion 5mg/kg. Usually 1-3 doses. Do not use in hepatitis — can worsen liver damage.
Second-line for steroid-refractory hepatitis. 500–1000mg twice daily oral. Monitor LFTs weekly. Azathioprine is an alternative.
Same irAE recurrence rate on rechallenge: ~30-40%. Different organ irAE can also occur.
CT interpretation, bronchoscopy for pneumonitis, BAL to exclude infection. Refer at Grade 2+ pneumonitis.
Colonoscopy for Grade 2+ colitis, infliximab decision, biopsy confirmation. Refer immediately.
Thyroid, adrenal, pituitary, pancreatic irAEs. Permanent hormone replacement protocols. Essential partner.
Grade 3+ skin irAEs, biopsy, management of rare SJS/TEN. Immediate referral for blistering rash.
Any suspected myocarditis — troponin + ECG + echo + cardiac MRI. High mortality if delayed. Urgent.
Encephalitis, Guillain-Barré, myasthenia. MRI brain, LP, nerve conduction studies. Urgent if acute confusion.
Check items to track completion. Saved locally in your browser.
Chimeric Antigen Receptor T-cell therapy involves genetically engineering a patient's own T-cells to express receptors targeting tumour antigens (CD19 for B-cell malignancies, BCMA for myeloma). The process takes 3-4 weeks from leukapheresis to infusion.
Collect patient T-cells via apheresis machine. Requires large-bore central access (PICC or Hickman catheter). Process takes 3-5 hours.
T-cells sent to manufacturing facility. Viral vector used to insert CAR gene. Process takes 3-4 weeks. Patient may receive bridging chemotherapy during this period.
Fludarabine + cyclophosphamide chemotherapy given 5-7 days before infusion to deplete existing T-cells and "make space" for CAR-T expansion. Nurse monitors for cytopenias, infections.
Single IV infusion (usually 15-30 min). Patient monitored in hospital for minimum 7 days post-infusion for CRS/ICANS. Requires certified inpatient CAR-T centre with 24/7 ICU backup.
| Grade | Description |
|---|---|
| 1 | Fever only (≥38°C) |
| 2 | Fever + hypotension responding to fluids OR O2 requirement <40% |
| 3 | Hypotension needing vasopressors OR O2 ≥40% |
| 4 | Life-threatening: mechanical ventilation or organ failure |
Tocilizumab (Actemra) is the cornerstone CRS treatment. Must be available 24/7 in any CAR-T centre. Each dose 8mg/kg IV over 1 hour. Maximum 3 doses.
Scored 0-10: Orientation (4 pts) + Naming (3 pts) + Commands (1 pt) + Writing (1 pt) + Attention (1 pt). ICE score helps grade ICANS severity.
| Grade | ICE Score | Management |
|---|---|---|
| 1 | 7-9 | Supportive care, fall precautions, frequent neuro check |
| 2 | 3-6 | Dexamethasone 10mg Q6H, neurology consult |
| 3 | 0-2 | Higher dose dexamethasone, HDU/ICU, EEG, levetiracetam |
| 4 | 0 (unrousable) | ICU, mechanical ventilation, methylprednisolone IV, urgent MRI |
Nursing checks: Hourly to 4-hourly neuro assessment post-CAR-T. Ask patient to write, name objects, follow commands. Document and escalate any change immediately.
Bispecific T-cell engager (BiTE) — simultaneously binds CD3 on T-cells and CD19 on B-cell malignancies. Used in ALL and DLBCL.
28-day CONTINUOUS IV infusion CRS + neurological toxicityUAE, Saudi Arabia & Qatar have the most comprehensive immunotherapy access — most approved checkpoint inhibitors are available through national formularies or insurance reimbursement. Biosimilar trastuzumab widely used for HER2+ breast cancer.
| Centre | Country | Capability |
|---|---|---|
| Cleveland Clinic Abu Dhabi | UAE | Full immunotherapy, emerging CAR-T |
| Mediclinic City Hospital | UAE (Dubai) | Checkpoint inhibitors, biologics |
| Hamad Medical Corp (HMC/NCCCR) | Qatar | Full immunotherapy programme |
| KFSHRC (King Faisal Specialist) | Saudi Arabia | Most advanced — CAR-T, bispecifics |
| KAMC (King Abdulaziz Medical) | Saudi Arabia | Checkpoint inhibitors, HER2 biologics |
| Aster Hospital Network | UAE/GCC | Standard checkpoint inhibitors |
Many GCC patients and families have a strong preference for curative intent treatment rooted in religious and cultural values around life and hope. Immunotherapy given in the palliative setting can create complex consent discussions — some families may misunderstand "immunotherapy" as more potent/curative than chemotherapy.
Fasting during Ramadan creates specific challenges for immunotherapy patients. Dehydration increases risk of renal irAEs (nephritis) and can worsen GI irAEs (colitis). Colitis patients particularly at risk of dehydration during fasting.
The Oncology Nursing Society (ONS) Chemotherapy-Biotherapy Certificate is the primary certification for immunotherapy nursing competence in GCC oncology settings. It covers immunotherapy, targeted therapy, and biologic agents including checkpoint inhibitors.